Enhancement of somatostatin-receptor-targeted 177Lu-[DOTA0-Tyr3]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation

« Previous Next »Nuclear Medicine and Biology
Volume 35, Issue 6 , Pages 673-678, August 2008

Enhancement of somatostatin-receptor-targeted ¹⁷⁷Lu-[DOTA⁰-Tyr³]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation

Tapan K. Nayak
- College of Pharmacy, University of New Mexico, Albuquerque, NM 87131, USA
- Department of Cell Biology and Physiology, School of Medicine, University of New Mexico, Albuquerque, NM 87131, USA
- Current address: Radiation Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA.
Robert W. Atcher
- College of Pharmacy, University of New Mexico, Albuquerque, NM 87131, USA
- Bioscience Division, Los Alamos National Laboratory, Los Alamos, NM 87545, USA
Eric R. Prossnitz
- Department of Cell Biology and Physiology, School of Medicine, University of New Mexico, Albuquerque, NM 87131, USA
- Cancer Research and Treatment Center, University of New Mexico, Albuquerque, NM 87131, USA
Jeffrey P. Norenberg
- College of Pharmacy, University of New Mexico, Albuquerque, NM 87131, USA
- Cancer Research and Treatment Center, University of New Mexico, Albuquerque, NM 87131, USA
- Corresponding author. College of Pharmacy, University of New Mexico, Albuquerque, NM 87131 0001, USA.